Rapid Dose Therapeutics Announces Shareholder Meeting Voting Results and New Chief Financial Officer

BURLINGTON, Ontario, Dec. 06, 2019 (GLOBE NEWSWIRE) -- Rapid Dose Therapeutics Corp. (CSE: DOSE) (“RDT” or the “Corporation”) is pleased to announce that all of the nominees listed in the Corporation’s management information circular dated November 11, 2019 were elected as directors of the Corporation at the Annual General and Special Meeting of Shareholders held today, Friday, December 6, 2019 (the “Meeting”) and all of the other matters considered by the shareholders at the Meeting were approved.

The following table provides detailed proxy results of matters considered and voted upon at the Meeting:

Matters Voted Upon at the Meeting			Percentage
1.  Re-Appointment of MNP LLP as Auditor	Votes in Favour  Votes Withheld	41,114,985 400	99.9% 0.0009%
2.  Authorization for the Board to Change the Number of Directors between Shareholders Meetings	Votes in Favour Votes Against	41,114,985 400	99.9% 0.0009%
3.  Election of Directors      a.     Mark Upsdell	Votes in Favour Votes Withheld	40,792,169 323,216	99.2% 0.78%
b.     Kenneth Fox	Votes in Favour Votes Withheld	41,114,985 400	99.9% 0.0009%
c.     Donald Sheldon	Votes in Favour Votes Withheld	39,714,985 1,400,000	96.5% 3.4%
4.  Approval of Stock Option Plan	Votes in Favour Votes Against	38,776,785 2,338,600	94.3% 5.6%

The Corporation also announces that Ian Fodie, the current Chief Financial Officer of the Corporation, has resigned with an ending date of December 10, 2019.  “On behalf of the entire Board and management of the Corporation, I would like to thank Ian for his tireless efforts and assistance during his tenure as CFO of our Corporation and wish him every possible success in his future endeavours,” said Mark Upsdell, Chief Executive Officer of RDT.